QHSLab Inc - USAQ STOCK NEWS

QHSLab, Inc. (USAQ) has launched a new digital health tool for assessing post-COVID conditions in primary care patients. According to the CDC, 1 in 5 adults may have health issues related to past COVID infections. This tool aims to support primary care physicians (PCPs) by providing reimbursable assessments for symptoms like fatigue, pain, and cognitive issues. With an estimated reimbursement of $100 per encounter, QHSLab's innovation is expected to enhance PCP revenue streams, potentially generating over $80,000 annually per client. Management believes the current stock price does not reflect the company's true value.

QHSLab, Inc. (OTCQB: USAQ) has announced a strategic alliance with Medical License Factory to enhance its independent practitioner network and expand the adoption of its AllergiEnd® allergy diagnostic products. This partnership aims to provide administrative, billing, and marketing support, addressing industry challenges such as inflation and rising labor costs. CEO Troy Grogan emphasized the alliance's role in offering physicians ongoing revenue streams. The collaboration aims to bolster clinical outcomes and operational efficiency for medical practices, thereby strengthening QHSLab's market position.

QHSLab, Inc. (OTCQB: USAQ) released a letter from CEO Troy Grogan addressing market conditions and quarterly performance. The company reported a 17% increase in revenue to $355,330 and a 41% surge in gross profit to $188,688 for Q1 2022. Despite a 20% decrease in net operating loss to $61,127, the company faced inventory challenges due to shipping delays. Looking ahead, QHSLab plans to introduce a new product, AllergiQT, targeting a $90M annual market. The CEO emphasized confidence in the company’s growth potential amid challenging market dynamics.

QHSLab, Inc. (OTCQB: USAQ) projects a $90 million annual addressable market for its new product, the AllergiQT™ – Quick Test, aimed at providing cost-effective, in-office allergy testing for primary care physicians. This test simplifies allergy diagnostics, eliminating the need for blood draws and providing results in under 15 minutes. The company targets over 250,000 primary care physicians in the U.S. to capture a larger segment of the allergy testing market, which serves more than 60 million patients annually. The AllergiQT™ test represents a significant advancement in value-based care.

QHSLab, Inc. (OTCQB: USAQ) has validated its business model through repeat orders and product expansion. The addressable market includes over 250,000 independent primary care physicians, with expected annual revenue of $10,000 per practice. The company aims to leverage digital health, point-of-care, and virtual care services, aligning with industry trends heightened by the COVID-19 pandemic. CEO Troy Grogan highlighted growth to $1.4 million in revenue with plans for strategic acquisitions to enhance product offerings and distribution networks.

QHSLab, Inc. (formerly USA Equities Corp) has officially changed its name following FINRA approval, marking a significant milestone in its growth. The company specializes in digital health solutions and point-of-care diagnostic tests for primary care physicians. The name change reflects the strong brand recognition of its flagship product, QHSLab, and follows a successful financial year in 2021. CEO Troy Grogan highlighted the launch of new digital products in 2022 as part of the company’s expansion strategy.

USA Equities Corp (OTCQB: USAQ) reported a remarkable financial performance for 2021, with total revenues of $1.4 million, up 265% from $124,000 in 2020. The company achieved a gross margin of 52% in Q4, reflecting a significant improvement. Key drivers included the acquisition of AllergiEnd® assets, generating $329,989 in Q4 sales and approximately $5 million in revenue for physician clients. With total assets of $2.2 million, USAQ is poised for growth, pending a name change to QHSLab, Inc.

USA Equities Corp (OTCQB: USAQ) is expanding its digital healthcare offerings in 2022, introducing new point-of-care clinical tools. A key product is the Q-Scale, a mental health risk assessment tool, aimed at addressing the mental health crisis affecting nearly 53 million Americans. Additionally, a new application for musculoskeletal health and chronic pain management targets a $130B market. The QHSLab, the company's flagship clinical decision support system, enhances physician efficiency and improves patient care, focusing on proactive healthcare solutions.

USA Equities Corp (OTCQB: USAQ) recently highlighted additional validation for its digital medicine platform, QHSLab, following a JAMA study showcasing successful patient outcomes for chronic disease management. The study indicated that digital health interventions can reduce hospitalizations, aligning with USAQ's mission to support primary care physicians. The QHSLab platform enhances chronic condition management with evidence-based interventions and aims to release new reimbursable tools. USAQ is also in the process of rebranding itself as QHSLab, Inc. to reflect its focus on digital health solutions.